News | Oncology Related Products | March 15, 2016

Pyrexar Medical Buys Back Outside Ownership from Person Medical

Company regains full ownership, including royalties on BSD-2000 Hyperthermia System

Pyrexar, buy back outside ownership, Person Medical, BSD-2000 Hyperthermia System

BSD-2000 image courtesy of Pyrexar Medical

March 15, 2016 — Pyrexar announced it has purchased back outside ownership from Person Medical (formerly BSD Medical), concluding a purchase agreement made by the two companies in 2015.

In the original agreement, Pyrexar purchased the hyperthermia device group from Person. In exchange, Person Medical acquired 19.9 percent of Pyrexar, along with royalties on future sales of the BSD-2000 Hyperthermia System, Pyrexar’s flagship product. The royalties were valued at an estimated $4 million over the next three years.

Pyrexar announced several other business developments, including:  

  • New distribution — The company added nine new international distribution companies, with several more in negotiation to bring sales coverage to 31 countries;
  • Revamped manufacturing workflow — The company increased the speed of its manufacturing process by 600 percent;
  • Regulatory process — The company added Taiwan Food and Drug Administration (TFDA), Korean FDA, TUV Rheinland and Restriction of Hazardous Substances Directive (RoHs) compliance to their process; and
  • Engineering updates — Manufacturing processes are being re-engineered to be more efficient and cost effective. The company is also exploring new thermal therapy products.

For more information:

Related Content

Varian Purchasing Embolic Bead Assets from Boston Scientific
News | Interventional Radiology | July 03, 2019
Varian announced it has signed an asset purchase agreement to acquire the Boston Scientific portfolio of drug-loadable...
FDA Approves Exablate Neuro for Tremor-Dominant Parkinson's Treatment
Technology | Focused Ultrasound Therapy | December 21, 2018
Insightec announced that the U.S. Food and Drug Administration (FDA) has approved an expansion of the indication of...
Videos | Radiation Oncology | November 06, 2018
Genomics can be used to assess a patient's radiosensitivity, which can be used to increase or decrease the radiation
News | Radiation Dose Management | September 24, 2018
AngioDynamics Inc. announced an agreement to acquire RadiaDyne, a privately held medical diagnostic and device company...
​ITN Celebrates World Cancer Day 2018
News | Radiation Oncology | February 01, 2018
World Cancer Day takes place annually on Feb.
MR-HIFU, ThermoDox, combination therapy, recurrent childhood tumors, Celsion, Children's National Health System, Phase I clinical study
News | Oncology Related Products | December 19, 2016
December 19, 2016 — Children’s National Health System and Celsion Corp.
News | Clinical Decision Support | October 27, 2016
October 27, 2016 — The National Comprehensive Cancer Network (NCCN) continues to build its library of appropriate use
contrast-enhanced ultrasound, CEUS, liver cancer, hepatocellular carcinoma, study, Advances in Contrast Ultrasound conference, ICUS
News | Ultrasound Imaging | September 12, 2016
September 12, 2016 — Tiny microbubbles are being used to more effectively...
cardio-oncology, echo strain assessment, echoinsight, epsilon

Epsilon's EchoInsight software helps analyze cardiac function by evaluating wall motion strain. 

Feature | Cardio-oncology | May 13, 2016 | Dave Fornell
Cardio-oncology is an emerging field that combines the expertise of both cardiology and oncology to assess and treat